Vertex Pharmaceuticals Incorporated (VRTX) stock analysis

In our weekly check, Vertex Pharmaceuticals Incorporated is graded B (A to F). Of 24 checks on debt, profit, cash flow and trend: 20 pass, warnings: 3, red flags: 1.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as VRTX.

What our checks show for VRTX

Red flags

Warning signs

Strengths

Next earnings report: 2027-02-11

Similar companies

REGN · MRNA · ARGX · ONC · RVMD · GMAB

Questions

What grade does Vertex Pharmaceuticals Incorporated (VRTX) have?

In our weekly check, Vertex Pharmaceuticals Incorporated is graded B (A to F). Of 24 checks on debt, profit, cash flow and trend: 20 pass, warnings: 3, red flags: 1. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of VRTX stock?

This week's biggest flags for Vertex Pharmaceuticals Incorporated: Deep past fall, Gross margin falling, High P/E. In total 4 of 24 checks show a warning or a red flag.

What does Vertex Pharmaceuticals Incorporated do?

Vertex Pharmaceuticals Incorporated is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as VRTX.

When does Vertex Pharmaceuticals Incorporated report earnings next?

The next earnings report is expected on 2027-02-11. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis